M&A Deal Summary |
|
|---|---|
| Date | 2023-04-17 |
| Target | Satsumarx |
| Sector | Life Science |
| Buyer(s) | Shin Nippon Biomedical Laboratories |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1957 |
| Sector | Life Science |
| Employees | 1,541 |
| Revenue | 32.4B JPY (2025) |
Shin Nippon Biomedical Laboratories is a provider of single-dose toxicity studies, repeated dose toxicity tests, and cancer protozoal tests. Shin Nippon Biomedical Laboratories was founded in 1957 and is based in Kagoshima, Japan.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2023 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-02-28 |
Shin Nippon Biomedical Laboratories Clinical Pharmacology Center
Baltimore, United States Shin Nippon Biomedical Laboratories Clinical Pharmacology Center, Inc. (SNBL CPC) is a clinical pharmacology facility located in the University of Maryland BioPark in Baltimore, Maryland, USA. The state of the art facility and equipment is bolstered by a vibrant research community. SNBL CPC specializes in complex Phase I-II trials, including TQT/Phase 1 QT de-risking, first-In-human (FIH), Japanese Bridging and Phase II Proof of Concept (POC) studies in therapeutics areas including immunology/infectious disease, neurology, respiratory, dermatology and more. |
Sell | - |
